ImmunoGen Inc. (IMGN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for IMGN in the last 30 days. The most recent was published Jan 22, 2025.
Latest news
25 items- PRAntibody Drug Conjugates Market Size is Expected to Reach USD 25.38 Billion by 2033, Growing at a CAGR of 8.84%: Straits ResearchNew York, United States, Jan. 22, 2025 (GLOBE NEWSWIRE) -- ADCs, or antibody-drug conjugates, are chemotherapeutic agents explicitly designed to treat cancer cells. Antibody-drug conjugates deliver chemotherapy by fusing a linker to a monoclonal antibody that attaches to a specific target expressed on cancer cells. Inside the cancer cell, a poisonous chemical is released when the ADC attaches to its intended target (a cancer protein or receptor). Linkers, drugs or poisons, monoclonal antibodies, and others are among the most prevalent types of antibody-drug conjugates. A single white blood cell is cloned in order to produce monoclonal antibodies. Each successive antibody produced in this m
- PRPureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial OfficerFormer ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T
- PRSeaport Therapeutics Names Lauren White as Chief Financial OfficerFormer ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme
- FDAMarch 26, 2024 - FDA Roundup: March 26, 2024For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of
- FDAFDA Approval for ELAHERE issued to IMMUNOGEN INCSubmission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:
- SECSEC Form 15-12G filed by ImmunoGen Inc.15-12G - ImmunoGen, Inc. (0000855654) (Filer)
- 13D/GSEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)
- 13D/GSEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)
- 13D/GSEC Form SC 13G/A filed by ImmunoGen Inc. (Amendment)SC 13G/A - ImmunoGen, Inc. (0000855654) (Subject)
- INSIDERMitchell Dean J returned 103,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERSEC Form 4 filed by Peterson Kristine4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERThackray Helen M. returned 3,074 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDEREnyedy Mark J returned 584,397 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERWallace Richard John returned 10,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERCoen Stacy Ann returned 73,274 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERLentini Renee returned 14,723 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERGoldberg Mark Alan returned 60,720 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERArbuckle Stuart A returned 5,381 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERWingrove Theresa returned 21,039 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERSEC Form 4 filed by Mccluski Stephen C4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERSEC Form 4 filed by Mccain Tracey L4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERSEC Form 4 filed by Kalofonos Isabel4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERSEC Form 4 filed by White Lauren4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERChar Daniel returned 1,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
- INSIDERVasconcelles Michael returned 1,327 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - ImmunoGen, Inc. (0000855654) (Issuer)
IMGN FAQ
8 questionsWhat does ImmunoGen Inc. do?
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with...What is the latest news on IMGN?
Quantisnow has not tracked any new filings, ratings or press releases for IMGN in the last 30 days. The most recent wire item was published on January 22, 2025.Where does IMGN stock trade?
ImmunoGen Inc. (IMGN) is listed on NASDAQ.What sector and industry is IMGN in?
ImmunoGen Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ImmunoGen Inc. go public?
ImmunoGen Inc. (IMGN) completed its IPO in 1989.What are analysts saying about IMGN?
ImmunoGen Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Neutral with a $3100.00 price target on 2023-12-01.What companies are similar to IMGN?
Notable peers in the same industry include MRSN (Mersana Therapeutics Inc.), ADCT (ADC Therapeutics SA), GLYC (GlycoMimetics Inc.). Compare IMGN side-by-side with any of them on Quantisnow.How can I track IMGN on Quantisnow?
Quantisnow aggregates ImmunoGen Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMGN to receive live email and push alerts on every new disclosure.